Ubiquitination and adaptive responses to BRAF inhibitors in Melanoma
MetadataShow full item record
© 2018, © 2018 The Author(s). Published by Taylor & Francis. Response to targeted therapies is limited by the activation or inhibition of feedback loops. Here we report the ubiquitin specific peptidase 28/F-box WD repeat-containing protein 7 (USP28/FBW7) complex functions as a negative regulator of mitogen-activated protein kinase (MAPK) pathway by targeting v-raf murine sarcoma viral oncogene homolog B (BRAF) for degradation, a process which is lost in a large proportion of BRAF mutant melanoma patients, resulting in resistance to BRAF inhibitor therapies.
Showing items related by title, author, creator and subject.
Bentel, J.; Thomas, M.; Rodgers, J.; Arooj, Mahreen; Gray, E.; Allcock, R.; Fermoyle, S.; Mancera, R.; Cannell, P.; Parry, J. (2017)BRAF mutation testing to determine eligibility for treatment with vemurafenib was performed on archival skin lesions of a 54-year-old patient diagnosed with Erdheim-Chester disease (ECD) in 1999. Sanger sequencing of DNA ...
Saei, A.; Palafox, M.; Benoukraf, T.; Kumari, N.; Jaynes, P.; Iyengar, P.; Muñoz Couselo, E.; Nuciforo, P.; Cortés, J.; Nötzel, C.; Kumarakulasinghe, N.; Richard, J.; Isa, Z.; Pang, B.; Guzman, M.; Siqin, Z.; Yang, H.; Tam, W.; Serra, V.; Eichhorn, Pieter (2018)© 2018 Saei et al. RAF kinase inhibitors are clinically active in patients with BRAF (V600E) mutant melanoma. However, rarely do tumors regress completely, with the majority of responses being short-lived. This is partially ...
Cenin, Dayna; Naber, S.; Lansdorp-Vogelaar, Iris; Jenkins, M.; Buchanan, D.; Preen, D.; Ee, H.; O'Leary, Peter (2018)© 2018 The Authors Journal of Gastroenterology and Hepatology published by Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd Background and Aim: Individuals with Lynch syndrome ...